clinical trial · NCT06267846
A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder
Major Depressive DisorderNBI-1070770Placebo
brief summary
To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on improving symptoms of depression in participants with major depressive disorder (MDD).
started
Mar 20, 2024
primary completion
Jul 25, 2025
completion
Sep 11, 2025
last updated
Jul 17, 2026
official title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1070770 in Adults With Major Depressive Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol